Antibiotic Treatment for Multidrug-Resistant Enterobacter cloacae
For severe infections caused by multidrug-resistant (MDR) Enterobacter cloacae, use meropenem-vaborbactam or ceftazidime-avibactam as first-line therapy if the organism is susceptible in vitro. 1
Treatment Algorithm Based on Infection Severity and Resistance Pattern
Severe Infections (BSI, Septic Shock, HAP/VAP)
For carbapenem-resistant E. cloacae:
- First choice: Meropenem-vaborbactam or ceftazidime-avibactam (if active in vitro) 1
- If metallo-β-lactamase producer or resistant to above agents: Cefiderocol 1
- If resistant to all new β-lactam/β-lactamase inhibitors (BLBLI): Aztreonam + ceftazidime-avibactam combination 1
- If only susceptible to older agents: Combination therapy with ≥2 active drugs from polymyxins, aminoglycosides, tigecycline, or fosfomycin 1
Critical caveat: Do NOT use tigecycline for bloodstream infections or pneumonia due to poor outcomes 1. If absolutely necessary for pneumonia, use high-dose tigecycline only 1.
For carbapenem-susceptible but 3rd-generation cephalosporin-resistant E. cloacae:
- Preferred: Carbapenems (imipenem or meropenem) 1
- Avoid: New BLBLI agents—these should be reserved for carbapenem-resistant organisms per antibiotic stewardship 1
Non-Severe Infections
For carbapenem-resistant E. cloacae:
- Select an "old" antibiotic based on individual susceptibility testing and infection site 1
- For complicated UTI specifically: Aminoglycosides (including plazomicin) preferred over tigecycline 1
- Monotherapy is acceptable for low-risk infections 1
For carbapenem-susceptible E. cloacae:
- Consider piperacillin-tazobactam, amoxicillin-clavulanate, or quinolones (if susceptible) 1
- For uncomplicated UTI: Cotrimoxazole may be appropriate 1
- For UTI without septic shock: Aminoglycosides (short course) or IV fosfomycin 1
Combination vs. Monotherapy Guidance
Do NOT use combination therapy if treating with new BLBLI agents (ceftazidime-avibactam, meropenem-vaborbactam) or cefiderocol when the organism is susceptible 1. This is a strong recommendation based on lack of added benefit.
DO use combination therapy when:
- Treating severe infections with only polymyxins, aminoglycosides, tigecycline, or fosfomycin available 1
- Polymyxin-based regimens are preferred as combination over monotherapy 2
- Consider polymyxin + carbapenem if meropenem MIC ≤8 mg/L, using extended-infusion meropenem (3 hours) 1, 2
Specific Antibiotic Considerations
Carbapenems: Remain highly effective—resistance rates <8.6% in recent surveillance 3. Amikacin also shows excellent activity (1.6% resistance) 3.
Polymyxins (colistin):
- Monitor renal function closely and perform therapeutic drug monitoring when possible 2
- Avoid combining with other nephrotoxic or ototoxic drugs 2
- Dosing conversion critical: 1 million U colistin = 80 mg CMS = 33 mg CBA 2
Fosfomycin: Resistance genes (fosA, fosA3, fosA4) detected in 65-20% of resistant isolates 4. Reserve for susceptible organisms only.
Tigecycline: High resistance rates (36.7% in some series) 4. Strongly avoid for bloodstream infections and pneumonia 1.
Omadacycline: Case report evidence suggests potential utility for skin/soft tissue infections caused by carbapenem-resistant E. cloacae 5, though not included in formal guidelines.
De-escalation Strategy
Once clinically stabilized, step down from carbapenems to oral agents based on susceptibility: quinolones, cotrimoxazole, or older BLBLI agents 1. This is good clinical practice for antibiotic stewardship.
Critical Pitfalls to Avoid
- Do not use cephamycins (cefoxitin) or cefepime for MDR E. cloacae 1
- Previous antibiotic therapy increases MDR risk 3-fold 3—obtain cultures before starting empiric therapy
- Species misidentification is common (74% error rate with conventional methods) 6, 7—treat all Enterobacter cloacae complex as potentially related in outbreak settings
- Avoid carbapenem-based combinations unless meropenem MIC ≤8 mg/L and new BLBLI unavailable 1